# An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate

> **NCT00913263** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lidds AB** · enrollment: 24 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 2-hydroxyflutamide (2-HOF) [Liproca Depot]
- **DRUG:** 2-Hydroxyflutamide

## Key facts

- **NCT ID:** NCT00913263
- **Lead sponsor:** Lidds AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-05
- **Final completion:** 2011-07
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2015-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913263, "An Efficacy and Safety Study With Licroca Depot, a Controlled Release Product, Injected Into the Prostate". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00913263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*